Press Releases
 
Press Releases
  Date Title and Summary View
Jan 12, 2015
Fourth-quarter revenue of approximately $1.5 Million with more than 4,000 tests completed in 2014 MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq:EXAS) today announced that during 2014 it completed and reported a diagnostic result for 4,024 Cologuard tests, ...
Jan 9, 2015
MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) today announced that Scott Coward has been named Senior Vice President and General Counsel for the company effective January 1, 2015. "Scott is a talented lawyer whose extensive legal and healthcare industry exp...
Jan 6, 2015
MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco. Kevin T. Conroy, the company's chairman and chief executive, will make Exact Science's presentation at 9 a.m. P...
Jan 2, 2015
MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq:EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) has published an updated 2015 Clinical Laboratory Fee Schedule, which includes reimbursement for Exact Sciences' Cologuard® noninvasive colon cancer screening test (CP...
Dec 19, 2014
MADISON, Wis.--(BUSINESS WIRE)-- The Centers for Medicare and Medicaid Services (CMS) has informed representatives of Exact Sciences that next week the agency will be issuing a correction to the 2015 lab fee schedule. Consistent with the November 25th final payment decision, CMS will reimburse Cologuard based ...
Dec 19, 2014
MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) — The reimbursement amount published today for Cologuard in the 2015 Clinical Diagnostic Laboratory Fee Schedule is inconsistent with what the Centers for Medicare and Medicaid Services (CMS) publicly communicated on November 25, ...
Dec 16, 2014
MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corporation (NASDAQ: EXAS) today announced the pricing of the public offering of 4,000,000 common shares previously sold to Jefferies LLC and Robert W. Baird & Co. Incorporated, as underwriters of the offering. The common shares will be sold at a public offering pri...
Dec 15, 2014
MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corporation (NASDAQ: EXAS) today announced an agreement to sell 4,000,000 shares of its common stock to Jefferies LLC and Robert W. Baird & Co. Incorporated as underwriters in an underwritten public offering pursuant to its effective shelf registration statement ...
Dec 2, 2014
First and only FDA-approved noninvasive stool DNA screening test for colorectal cancer MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) today announced that Mercy Hospital St. Louis will now offer Cologuard®, the first and only FDA-approved noninvas...
Nov 25, 2014
CMS payment level supports patient access to the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) today announced that the Centers for Medicare & Medicaid Services (CMS) has is...
Page:
1
... NextLast
= add release to Briefcase